KAZAN, Russian Federation, April 6 /PRNewswire-FirstCall/ - Neuro-Biotech Corp.
(Pink Sheets: MRES) (OTCQB) Mr. Rustern Yusupov Vice-President
Neuro-Biotech Corp. Is pleased to announce that after discussions
between Neuro-Biotech Corp and Credo-TM the company approved the new
direction of the company. Mr. Yusupov said that the both Company Boards
have approved the immediate implementation of the business plan that
has been in development for the past few months. And following the
meeting with Auric Pharma Science, the new board has decided not to
pursue any longer the unsolicited offer that was made by Auric, since
after long discussions both companies were not able to agree on a
common direction for Neuro-Biotech.
Mr. Yusupov also said that a third party has been identified to produce
the test kit, also two laboratories that met Neuro-Biotech's tests
standards that have the qualified technical personnel. Neuro-Biotech
will be providing the required laboratory technician to train the
personnel in implementing Neuro-biotech's testing procedures.
Also Mr. Yusupov added that on March 28th, during the Quebec/Russia
Innovations Forum which was held in Montreal Technoparc Neuro-Biotech's
representative made a presentation to the deputy minister of Ministry
of Economical Development of Russian Federation, since Bio-technology
field is a major interest for the Russian government and
Neuro-Biotech's has developed a very unique and innovative products
which is ready to market. This makes Neuro-Biotech to qualify for major
private and Russian government funding and grants.
"Every one at Neuro-Biotech is anxious to start producing our products
Now that all elements are in place and our product is in great demand
as it assists the medical field to provide easy and fast diagnostic
treatment to their patient, this will also help private and public
institutions to save millions of dollars in unnecessary expenses."
Stated Mr. Yusupov.
Forward Looking Statements
This release contains statements that are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Act of 1995.
Certain statements in this press release may contain words such as
"anticipates," "believes," "could," "expects," "intends," "may,"
"projects," "targets" and other similar language that is considered
forward-looking statements. These forward-looking statements are
subject to certain risks and uncertainties and persons reading this
release are cautioned that such statements are only predictions, and
that the Company's actual future results or performance may be
materially different. The Company disclaims any intention or obligation
to update or revise forward-looking information, whether as a result of
new information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
SOURCE Neuro-Biotech Corp.